NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 367
(Total Views: 230)
Posted On: 08/23/2022 4:52:03 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals is conducting a potentially pivotal global phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used in the treatment of GBM patients as the tumor progresses. Patients are being enrolled at 19 sites thus far, with 42 more anticipated across the United States, Italy, France, Spain and Switzerland now that European regulatory approvals have been granted. The U.S. Food and Drug Administration (‘FDA’) has granted ‘fast-track’ and ‘orphan drug’ status to Berubicin, demonstrating the value of CNS’s initial successes in opening regulatory pathways for the drug’s market priority if it can continue to show success in its trial stage.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals is conducting a potentially pivotal global phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a standard-of-care chemotherapy agent used in the treatment of GBM patients as the tumor progresses. Patients are being enrolled at 19 sites thus far, with 42 more anticipated across the United States, Italy, France, Spain and Switzerland now that European regulatory approvals have been granted. The U.S. Food and Drug Administration (‘FDA’) has granted ‘fast-track’ and ‘orphan drug’ status to Berubicin, demonstrating the value of CNS’s initial successes in opening regulatory pathways for the drug’s market priority if it can continue to show success in its trial stage.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)